134 related articles for article (PubMed ID: 38043712)
1. Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States.
Carlson J; Foos V; Kasle A; Mugwagwa T; Draica F; Lee Wiemken T; Nguyen JL; Cha-Silva A; Migliaccio-Walle K; Dzingina M
Value Health; 2024 Feb; 27(2):164-172. PubMed ID: 38043712
[TBL] [Abstract][Full Text] [Related]
2. Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States.
Sandin R; Veenstra DL; Vankelegom M; Dzingina M; Sullivan SD; Campbell D; Ma C; Harrison C; Draica F; Wiemken TL; Mugwagwa T
J Manag Care Spec Pharm; 2023 Dec; 29(12):1290-1302. PubMed ID: 38058141
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
Butt AA; Yan P; Shaikh OS
PLoS One; 2024; 19(6):e0298254. PubMed ID: 38843201
[TBL] [Abstract][Full Text] [Related]
4. Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study.
Butt AA; Yan P; Shaikh OS; Talisa VB; Omer SB; Mayr FB
J Infect Dis; 2024 Jan; 229(1):147-154. PubMed ID: 37711076
[TBL] [Abstract][Full Text] [Related]
5. Cost-Utility Model of Nirmatrelvir/Ritonavir in Brazil: Analysis of a Vaccinated Population.
Fernandes RRA; Barros BM; da Costa MR; Magliano CAS; Tura BR; Morais QCD; Santos M
Value Health Reg Issues; 2024 Mar; 40():74-80. PubMed ID: 37995417
[TBL] [Abstract][Full Text] [Related]
6. Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation.
Kwok WC; Tam TCC; Ho JCM; Lam DCL; Ip MS; Ho PL
Int J Chron Obstruct Pulmon Dis; 2024; 19():77-86. PubMed ID: 38222320
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases.
Liu TH; Wu JY; Huang PY; Hsu WH; Chuang MH; Tsai YW; Lai CC; Huang CY
Expert Rev Anti Infect Ther; 2024; 22(1-3):121-128. PubMed ID: 37965890
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S
J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review.
Cha-Silva AS; Gavaghan MB; Bergroth T; Alexander-Parrish R; Yang J; Draica F; Patel J; Garner DA; Stanford RH; Meier G; McLaughlin JM; Nguyen JL
Am J Ther; 2024 May-Jun 01; 31(3):e246-e257. PubMed ID: 38691664
[TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
Wu JY; Chen CC; Liu MY; Hsu WH; Tsai YW; Liu TH; Pin-Chien S; Huang PY; Chuang MH; Lee MC; Hung KC; Yu T; Lai CC
J Med Virol; 2024 May; 96(5):e29662. PubMed ID: 38727085
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
Goswami H; Alsumali A; Jiang Y; Schindler M; Duke ER; Cohen J; Briggs A; Puenpatom A
Pharmacoeconomics; 2022 Jul; 40(7):699-714. PubMed ID: 35779197
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
Ombelet S; Castanares-Zapatero D; Desimpel F; Hulstaert F; Stordeur S; Roberfroid D
J Med Virol; 2024 Feb; 96(2):e29434. PubMed ID: 38376947
[TBL] [Abstract][Full Text] [Related]
13. Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.
Han X; Li C; Yuan X; Cui J; Han Z; Meng J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Chen W; Xiong J; Zhao D; Zhang X; Han X; Cheng H; Yu Z; Shi Y; Xie W; Xie L
Ann Med; 2024 Dec; 56(1):2313062. PubMed ID: 38354691
[TBL] [Abstract][Full Text] [Related]
14. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
Jang YR; Oh Y; Kim JY
J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic.
Denning K; Sheppard J; Carico R
J Am Pharm Assoc (2003); 2024; 64(2):530-534. PubMed ID: 38151202
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan.
Mizuno T; Kondo Y; Sakai M; Saneyasu K; Kojima R; Miyake Y
J Infect Chemother; 2024 Aug; 30(8):716-724. PubMed ID: 38325626
[TBL] [Abstract][Full Text] [Related]
17. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
Liu TH; Huang PY; Wu JY; Chuang MH; Hsu WH; Tsai YW; Chang CC; Lai CC
J Med Virol; 2023 May; 95(5):e28801. PubMed ID: 37218308
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
20. Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019.
Ganatra S; Dani SS; Ahmad J; Kumar A; Shah J; Abraham GM; McQuillen DP; Wachter RM; Sax PE
Clin Infect Dis; 2023 Feb; 76(4):563-572. PubMed ID: 35986628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
